<DOC>
	<DOCNO>NCT02534506</DOCNO>
	<brief_summary>The purpose study assess safety tolerability BMS-663513 subject advance and/or metastatic malignant tumor .</brief_summary>
	<brief_title>Study Urelumab Subjects With Advanced and/or Metastatic Malignant Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects previously treat advanced malignant solid tumor Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 1 For certain subject , willing able provide pretreatment tumor sample Known suspect central nervous system metastases central nervous system source disease Other concomitant malignancy ( exception per protocol ) Active , know suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Advanced malignant tumor</keyword>
	<keyword>Metastatic malignant tumor</keyword>
</DOC>